Score Overview
Explore the 2021 public Archive ranking →
Where ANI Pharmaceuticals Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ANIP
2012: 99.9% · 2021: 52.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 74.83 | — |
1 Year2025-09-26 | $ 93.05 | -19.58% |
5 Years2021-09-28 | $ 32.80 | 128.14% |
10 Years2016-09-28 | $ 67.66 | 10.60% |
20 Years2006-09-28 | $ 57.60 | 29.91% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 |
|---|---|---|---|---|---|
| Price | $ 74.83 | $ 93.05 | $ 32.80 | $ 67.66 | $ 57.60 |
| Return | — | -19.58% | 128.14% | 10.60% | 29.91% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 978M | $ 105M | $ 375M |
| 2025 | $ 883M | $ 78M | $ 285M |
| 2024 | $ 614M | -$ 18M | $ 151M |
| 2023 | $ 486M | $ 18M | $ 221M |
| 2022 | $ 316M | -$ 47M | $ 48M |
| 2021 | $ 216M | -$ 42M | $ 100M |
| 2020 | $ 208M | -$ 22M | $ 7M |
| 2019 | $ 206M | $ 6M | $ 62M |
| 2018 | $ 201M | $ 15M | $ 43M |
| 2017 | $ 176M | -$ 1M | $ 31M |
| 2016 | $ 128M | $ 3M | $ 27M |
| 2015 | $ 76M | $ 15M | $ 154M |
| 2014 | $ 55M | $ 28M | $ 169M |
| 2013 | $ 30M | $ 301K | $ 11M |
| 2012 | $ 2M | -$ 27M | $ 34M |
| 2011 | $ 435.16K | -$ 51M | $ 57M |
| 2010 | $ 2M | -$ 46M | $ 38M |
| 2009 | $ 1M | -$ 47M | $ 29M |
| 2008 | $ 3M | -$ 17M | $ 14M |
| 2007 | $ 493.05K | -$ 7M | $ 30M |
| 2006 | $ 14M | $ 2M | $ 11M |
| 2005 | $ 258.35K | -$ 9M | $ 9M |
| 2004 | $ 77.89K | -$ 12M | $ 17M |
| 2003 | $ 65.49K | -$ 5M | $ 9M |
| 2002 | $ 2M | -$ 3M | $ 4M |
| 2001 | $ 1M | -$ 2M | $ 4M |
| IPO2000 | -$ 3M | $ 2M |
ANI Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 208M to $ 883M and net income went from -$ 22M to $ 78M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 76M to $ 883M and net income grew from $ 15M to $ 78M. Revenue increased in every one of those 10 years; net income in 4.
ANI Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.6 out of 10. How the HDB Score is calculated.
Membership
Continue ANIP’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
